Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis von Moslehi, Javid J, Salem, Joe-Elie, Sosman, Jeffrey A, Lebrun-Vignes, Bénédicte, Johnson, Douglas B

Volltext

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance von Hugo, Willy, Shi, Hubing, Sun, Lu, Piva, Marco, Song, Chunying, Kong, Xiangju, Moriceau, Gatien, Hong, Aayoung, Dahlman, Kimberly B., Johnson, Douglas B., Sosman, Jeffrey A., Ribas, Antoni, Lo, Roger S.

Volltext

Melanoma: What do all the mutations mean? von Davis, Elizabeth J., Johnson, Douglas B., Sosman, Jeffrey A., Chandra, Sunandana

Volltext

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma von Hugo, Willy, Zaretsky, Jesse M., Sun, Lu, Song, Chunying, Moreno, Blanca Homet, Hu-Lieskovan, Siwen, Berent-Maoz, Beata, Pang, Jia, Chmielowski, Bartosz, Cherry, Grace, Seja, Elizabeth, Lomeli, Shirley, Kong, Xiangju, Kelley, Mark C., Sosman, Jeffrey A., Johnson, Douglas B., Ribas, Antoni, Lo, Roger S.

Volltext

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study von McDermott, David F, Sosman, Jeffrey A, Sznol, Mario, Massard, Christophe, Gordon, Michael S, Hamid, Omid, Powderly, John D, Infante, Jeffrey R, Fassò, Marcella, Wang, Yan V, Zou, Wei, Hegde, Priti S, Fine, Gregg D, Powles, Thomas

Volltext

Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction von Moriceau, Gatien, Hugo, Willy, Hong, Aayoung, Shi, Hubing, Kong, Xiangju, Yu, Clarissa C., Koya, Richard C., Samatar, Ahmed A., Khanlou, Negar, Braun, Jonathan, Ruchalski, Kathleen, Seifert, Heike, Larkin, James, Dahlman, Kimberly B., Johnson, Douglas B., Algazi, Alain, Sosman, Jeffrey A., Ribas, Antoni, Lo, Roger S.

Volltext

Non-viral precision T cell receptor replacement for personalized cell therapy von Foy, Susan P., Jacoby, Kyle, Bota, Daniela A., Hunter, Theresa, Pan, Zheng, Stawiski, Eric, Ma, Yan, Lu, William, Peng, Songming, Wang, Clifford L., Yuen, Benjamin, Dalmas, Olivier, Heeringa, Katharine, Sennino, Barbara, Conroy, Andy, Bethune, Michael T., Mende, Ines, White, William, Kukreja, Monica, Gunturu, Swetha, Humphrey, Emily, Hussaini, Adeel, An, Duo, Litterman, Adam J., Quach, Boi Bryant, Ng, Alphonsus H. C., Lu, Yue, Smith, Chad, Campbell, Katie M., Anaya, Daniel, Skrdlant, Lindsey, Huang, Eva Yi-Hsuan, Mendoza, Ventura, Mathur, Jyoti, Dengler, Luke, Purandare, Bhamini, Moot, Robert, Yi, Michael C., Funke, Roel, Sibley, Alison, Stallings-Schmitt, Todd, Oh, David Y., Chmielowski, Bartosz, Abedi, Mehrdad, Yuan, Yuan, Sosman, Jeffrey A., Lee, Sylvia M., Schoenfeld, Adam J., Baltimore, David, Heath, James R., Franzusoff, Alex, Ribas, Antoni, Rao, Arati V., Mandl, Stefanie J.

Volltext

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma von Hugo, Willy, Zaretsky, Jesse M., Sun, Lu, Song, Chunying, Moreno, Blanca Homet, Hu-Lieskovan, Siwen, Berent-Maoz, Beata, Pang, Jia, Chmielowski, Bartosz, Cherry, Grace, Seja, Elizabeth, Lomeli, Shirley, Kong, Xiangju, Kelley, Mark C., Sosman, Jeffrey A., Johnson, Douglas B., Ribas, Antoni, Lo, Roger S.

Volltext

High response rate to PD-1 blockade in desmoplastic melanomas von Eroglu, Zeynep, Zaretsky, Jesse M., Hu-Lieskovan, Siwen, Kim, Dae Won, Algazi, Alain, Johnson, Douglas B., Liniker, Elizabeth, Ben Kong, Munhoz, Rodrigo, Rapisuwon, Suthee, Gherardini, Pier Federico, Chmielowski, Bartosz, Wang, Xiaoyan, Shintaku, I. Peter, Wei, Cody, Sosman, Jeffrey A., Joseph, Richard W., Postow, Michael A., Carlino, Matteo S., Hwu, Wen-Jen, Scolyer, Richard A., Messina, Jane, Cochran, Alistair J., Long, Georgina V., Ribas, Antoni

Volltext

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events von Brahmer, Julie R, Abu-Sbeih, Hamzah, Ascierto, Paolo Antonio, Brufsky, Jill, Cappelli, Laura C, Cortazar, Frank B, Gerber, David E, Hamad, Lamya, Hansen, Eric, Johnson, Douglas B, Lacouture, Mario E, Masters, Gregory A, Naidoo, Jarushka, Nanni, Michele, Perales, Miguel-Angel, Puzanov, Igor, Santomasso, Bianca D, Shanbhag, Satish P, Sharma, Rajeev, Skondra, Dimitra, Sosman, Jeffrey A, Turner, Michelle, Ernstoff, Marc S

Volltext

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial von Weber, Jeffrey S, Prof, Gibney, Geoff, MD, Sullivan, Ryan J, MD, Sosman, Jeffrey A, Prof, Slingluff, Craig L, Prof, Lawrence, Donald P, MD, Logan, Theodore F, MD, Schuchter, Lynn M, Prof, Nair, Suresh, MD, Fecher, Leslie, MD, Buchbinder, Elizabeth I, MD, Berghorn, Elmer, BSN, Ruisi, Mary, MD, Kong, George, PhD, Jiang, Joel, PhD, Horak, Christine, PhD, Hodi, F Stephen, Dr

Volltext

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy von Johnson, Douglas B., Estrada, Monica V., Salgado, Roberto, Sanchez, Violeta, Doxie, Deon B., Opalenik, Susan R., Vilgelm, Anna E., Feld, Emily, Johnson, Adam S., Greenplate, Allison R., Sanders, Melinda E., Lovly, Christine M., Frederick, Dennie T., Kelley, Mark C., Richmond, Ann, Irish, Jonathan M., Shyr, Yu, Sullivan, Ryan J., Puzanov, Igor, Sosman, Jeffrey A., Balko, Justin M.

Volltext

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma von Flaherty, Keith T, Puzanov, Igor, Kim, Kevin B, Ribas, Antoni, McArthur, Grant A, Sosman, Jeffrey A, O'Dwyer, Peter J, Lee, Richard J, Grippo, Joseph F, Nolop, Keith, Chapman, Paul B

Volltext

Melanoma: Does Sequencing Really Matter? von Chandra, Sunandana, Choi, Jacob S, Sosman, Jeffrey A

Volltext

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma von Escudier, Bernard, Sharma, Padmanee, McDermott, David F, George, Saby, Hammers, Hans J, Srinivas, Sandhya, Tykodi, Scott S, Sosman, Jeffrey A, Procopio, Giuseppe, Plimack, Elizabeth R, Castellano, Daniel, Gurney, Howard, Donskov, Frede, Peltola, Katriina, Wagstaff, John, Gauler, Thomas C, Ueda, Takeshi, Zhao, Huanyu, Waxman, Ian M, Motzer, Robert J

Volltext

Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies von Zhai, Lijie, Bell, April, Ladomersky, Erik, Lauing, Kristen L, Bollu, Lakshmi, Sosman, Jeffrey A, Zhang, Bin, Wu, Jennifer D, Miller, Stephen D, Meeks, Joshua J, Lukas, Rimas V, Wyatt, Eugene, Doglio, Lynn, Schiltz, Gary E, McCusker, Robert H, Wainwright, Derek A

Volltext

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer von Topalian, Suzanne L, Hodi, F. Stephen, Brahmer, Julie R, Gettinger, Scott N, Smith, David C, McDermott, David F, Powderly, John D, Carvajal, Richard D, Sosman, Jeffrey A, Atkins, Michael B, Leming, Philip D, Spigel, David R, Antonia, Scott J, Horn, Leora, Drake, Charles G, Pardoll, Drew M, Chen, Lieping, Sharfman, William H, Anders, Robert A, Taube, Janis M, McMiller, Tracee L, Xu, Haiying, Korman, Alan J, Jure-Kunkel, Maria, Agrawal, Shruti, McDonald, Daniel, Kollia, Georgia D, Gupta, Ashok, Wigginton, Jon M, Sznol, Mario

Volltext

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) von Poulikakos, Poulikos I., Persaud, Yogindra, Janakiraman, Manickam, Kong, Xiangju, Ng, Charles, Moriceau, Gatien, Shi, Hubing, Atefi, Mohammad, Titz, Bjoern, Gabay, May Tal, Salton, Maayan, Dahlman, Kimberly B., Tadi, Madhavi, Wargo, Jennifer A., Flaherty, Keith T., Kelley, Mark C., Misteli, Tom, Chapman, Paul B., Sosman, Jeffrey A., Graeber, Thomas G., Ribas, Antoni, Lo, Roger S., Rosen, Neal, Solit, David B.

Volltext

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy von Shi, Hubing, Hugo, Willy, Kong, Xiangju, Hong, Aayoung, Koya, Richard C, Moriceau, Gatien, Chodon, Thinle, Guo, Rongqing, Johnson, Douglas B, Dahlman, Kimberly B, Kelley, Mark C, Kefford, Richard F, Chmielowski, Bartosz, Glaspy, John A, Sosman, Jeffrey A, van Baren, Nicolas, Long, Georgina V, Ribas, Antoni, Lo, Roger S

Volltext

Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor von KIM, Kevin B, KEFFORD, Richard, GONZALEZ, Rene, OTT, Patrick A, LONG, Georgina V, GARDNER, Olivia S, OUELLET, Daniele, YANMEI XU, DEMARINI, Douglas J, LE, Ngocdiep T, PATEL, Kiran, LEWIS, Karl D, PAVLICK, Anna C, INFANTE, Jeffrey R, RIBAS, Antoni, SOSMAN, Jeffrey A, FECHER, Leslie A, MILLWARD, Michael, MCARTHUR, GrantA, HWU, Patrick

Volltext